Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Palmetto Retina Center, LLC20 enrolled

Overview

The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.

Retinal venous occlusive disease, which includes central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), is second only to diabetic retinopathy as a cause of vision loss due to retinal disease. The main cause of vision loss in all of these disorders is the development of macular edema. Current clinical practice based on randomized controlled clinical trials (ETDRS, BVOS) employs laser photocoagulation, either in a focal or grid pattern, to treat macular edema associated with diabetic retinopathy and branch retinal vein occlusion. Unfortunately, laser photocoagulation is ineffective in central retinal vein occlusion (CRVO), and no proven therapy exists for CRVO. The pathogenesis of macular edema in retinal vascular diseases is generally accepted to be increased levels of vascular endothelial growth factor (VEGF) due to ischemic or other stimuli. VEGF is known to be one of the most potent stimulators of vascular leakage in humans. Therefore, it seems sensible to study inhibition of VEGF to reduce vascular leakage, reduce macular edema, and improve vision in these retinal vascular disorders. Phase 2 randomized, controlled clinical trials of Macugen in diabetic macular edema and in macular edema associated with CRVO have been conducted. In the diabetes trial, patients treated with Macugen had improved vision, reduced macular edema as measured by optical coherence tomography (OCT), and reduced need for laser treatment compared to patients treated with sham injections. In the CRVO trial, patients treated with Macugen 1 mg every 6 weeks for 24 weeks had improved vision and reduced macular edema at week 30 compared to sham. This is the first randomized trial of treatment for CRVO to show a benefit over control. Based on these positive findings, we plan to study Macugen treatment of macular edema due to BRVO.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Branch Retinal Vein Occlusion

Interventions

pegaptanib sodium (Macugen)DRUG

Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Macular edema secondary to BRVO involving the foveal center in male or female patients at least 18 years of age * Duration of BRVO macular edema less than 6 months prior to baseline visit * Best corrected ETDRS visual acuity 20/40-20/320 (Snellen equivalent) using the 4 meters testing method. * Central foveal thickness greater than or equal to 250 microns using the OCT-3 * Less than 25% of foveal capillary ring disruption * Less than 2 disc areas of capillary non-perfusion within 1000 microns of the foveal center * Absence of hemorrhage or lipid in the foveal center * Investigator comfortable deferring macular laser for 18 weeks from baseline and intravitreous steroid for 36 weeks from baseline Exclusion Criteria: * Ocular conditions other than BRVO related macular edema such as significant cataract, diabetic retinopathy, AMD, glaucoma, uveitis, epiretinal membrane, vitreomacular traction or tumor. * Intraocular surgery within past 3 months * Significant enlargement of foveal avascular zone(\>25% disruption of capillary ring) or greater than 2 disc areas of nonperfusion within 1000 microns of foveal center. * Likelihood of evidence driven indication for peripheral photocoagulation in the next 6 months. * Patients who have shown evidence of spontaneous improvement within the preceding 3 months, as determined by an improvement of \>15 letters of vision or thinning of the Center Point on OCT of \>20% from baseline determination * Prior grid laser within 4 months of baseline or more than one prior grid laser treatment. * No prior intravitreous or periocular steroid injections in the study eye.

Locations (3)

Jules Stein Eye Institute

Los Angeles, California, United States

Cumberland Valley Retina Center

Hagerstown, Maryland, United States

Palmetto Retina Center

West Columbia, South Carolina, United States

Outcomes

Primary Outcomes

Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks

Time frame: 54 Weeks

Secondary Outcomes

Standardized Change From Baseline in Macular Thickening Measured by OCT3 Using the Central Point of the Central Subfield

Time frame: 54 Weeks

Safety Parameters

Safety endpoints incuded all investigator reported ocular and systemic adverse events. All events were graded as mild moderate or severe and assessed as related or unrelated to the injection procedure and the study drug.

Time frame: 54 Weeks

Change in Central Subfield Thickness on OCT From Baseline to Week 54

Time frame: 54 Weeks

Change in Macular Volume on OCT From Baseline to Week 54

Time frame: 54 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.